SEC Tracker
Get the app
Person · CIK 1846905

Muna Bhanji

Director at Veracyte, Ardelyx, Intellia Therapeutics and Cytokinetics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$902K
Noticed on Form 144$887K
Bought on Form 4$0
Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Veracyte VCYTCommon StockDirectly40,854Oct 19, 2026 · Filing · EDGAR
Ardelyx ARDXCommon StockDirectly163,808Jun 16, 2026 · Filing · EDGAR
Ardelyx ARDXStock Option (Right to Buy)
exercise $5.67, expires Jun 16, 2036, into Common Stock
Directly39,715Jun 16, 2026 · Filing · EDGAR
Intellia Therapeutics NTLACommon StockDirectly36,403Jun 9, 2026 · Filing · EDGAR
Intellia Therapeutics NTLAStock Option (right to buy)
exercise $12.89, expires Jun 8, 2036, into Common Stock
Directly13,300Jun 9, 2026 · Filing · EDGAR
Cytokinetics CYTKCommon StockDirectly26,361May 27, 2026 · Filing · EDGAR
Cytokinetics CYTKNon-Qualified Stock Option (Right to Buy)
exercise $77.15, expires May 26, 2036, into Common Stock
Directly4,301May 27, 2026 · Filing · EDGAR

Sold and noticed by quarter

Muna Bhanji: dollars sold on Form 4 and noticed on Form 144 per quarter, Q2 2023 to Q4 2026$217K$0Q2 2023: $190K noticed on Form 144Q2 2023: $196K sold on Form 4Q3 2023: $153K noticed on Form 144Q3 2023: $153K sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $6K sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $217K noticed on Form 144Q2 2024: $215K sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $3K sold on Form 4Q2 2025: $166K noticed on Form 144Q2 2025: $168K sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $161K noticed on Form 144Q3 2026: $80K sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $81K sold on Form 4Q2 2023Q1 2024Q4 2024Q3 2025Q2 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2026$81K—
Q3 2026$80K$161K
Q2 2025$168K$166K
Q1 2025$3K—
Q2 2024$215K$217K
Q4 2023$6K—
Q3 2023$153K$153K
Q2 2023$196K$190K

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Veracyte VCYT · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 2, 2026 · 1 notice
Sep 1, 20263,728 · ~$161KSep 1, 2026Sold as noticed Sold 3,728 in 2 sales, Sep 1 to Oct 19 · $162K Form 4 (1) · Form 4 (2)Filing · EDGAR
Veracyte VCYT · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 11, 2024 · 1 notice
Jun 13, 20254,589 · ~$122KJun 13, 2025Sold as noticed Sold 4,589 at $26.67 on Jun 13 · $122K Form 4Filing · EDGAR
Cytokinetics CYTK · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 18, 2024 · 1 notice
May 15, 20251,454 · ~$44KMay 15, 2025Sold as noticed Sold 1,454 at $29.73 on May 15 · $43K Form 4Filing · EDGAR
Cytokinetics CYTK · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 11, 2024 · 1 notice
Jun 10, 20242,000 · ~$104KJun 10, 2024Sold as noticed Sold 2,000 at $52.07 on Jun 10 · $104K Form 4Filing · EDGAR
Veracyte VCYT · Morgan Stanley Smith Barney · 10b5-1 plan adopted Feb 27, 2024 · 1 notice
May 28, 20245,409 · ~$113KMay 28, 2024Sold as noticed Sold 5,409 in 2 sales, May 28 to Jun 10 · $111K Form 4 (1) · Form 4 (2)Filing · EDGAR
Intellia Therapeutics NTLA · E*Trade Financial · 10b5-1 plan adopted Mar 8, 2023 · 2 notices
Jul 31, 2023265 · ~$11KJul 31, 2023Sold as noticed Sold 265 at $42.33 on Jul 31 · $11K Form 4Filing · EDGAR
Jul 6, 20231,867 · ~$73KJul 6, 2023Sold as noticed Sold 1,867 at $39.30 on Jul 6 · $73K Form 4Filing · EDGAR
Cytokinetics CYTK · E*Trade Financial · 10b5-1 plan adopted Mar 9, 2023 · 1 notice
Jul 7, 20232,000 · ~$68KJul 7, 2023Sold as noticed Sold 2,000 at $34.12 on Jul 7 · $68K Form 4Filing · EDGAR
Veracyte VCYT · Morgan Stanley Smith Barney · 10b5-1 plan adopted Feb 27, 2023 · 1 notice
May 30, 20237,432 · ~$190KMay 30, 2023Sold as noticed Sold 7,432 in 3 sales, May 30 to Jun 16 · $196K Form 4 (1) · Form 4 (2)Filing · EDGAR
Sales without a matching Form 144 · 3 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Intellia Therapeutics (NTLA): Sold 265 at $8.50 on Apr 29, 2025 · $2K (10b5-1 plan)Filing · EDGAR
———Sold without notice Intellia Therapeutics (NTLA): Sold 265 at $9.97 on Jan 29, 2025 · $3K (10b5-1 plan)Filing · EDGAR
———Sold without notice Intellia Therapeutics (NTLA): Sold 265 at $23.90 on Oct 31, 2023 · $6K (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Veracyte VCYT Director · filings 2021 to 2026 · sold $591K · $586K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Oct 19, 2026Sale under a 10b5-1 plan−1,864$43.70$81K40,854 directFiling · EDGAR
Sep 1, 2026Sale under a 10b5-1 plan−1,864$42.97$80K42,718 directFiling · EDGAR
Jun 11, 2026Grant or award from the company+5,27244,582 directFiling · EDGAR
Jun 18, 2025Grant or award from the company+9,32139,310 directFiling · EDGAR
Jun 13, 2025Sale under a 10b5-1 plan−4,589$26.67$122K29,989 directFiling · EDGAR
Jun 13, 2024Grant or award from the company+11,47334,578 directFiling · EDGAR
Jun 10, 2024Sale under a 10b5-1 plan−3,870$20.32$79K23,105 directFiling · EDGAR
May 28, 2024Sale under a 10b5-1 plan−1,539$21.00$32K26,975 directFiling · EDGAR
Jun 16, 2023Sale under a 10b5-1 plan−5,793$26.42$153K28,614 directFiling · EDGAR
Jun 16, 2023Sale under a 10b5-1 plan−100$27.09$3K28,514 directFiling · EDGAR
Jun 9, 2023Grant or award from the company+9,67434,407 directFiling · EDGAR
May 30, 2023Sale under a 10b5-1 plan−1,539$25.91$40K24,733 directFiling · EDGAR
Jun 16, 2022Grant or award from the company+14,73126,272 directFiling · EDGAR
Mar 19, 2021Grant or award from the company+11,54111,541 directFiling · EDGAR

Ardelyx ARDX Director · filings 2021 to 2026

DateTransactionSharesPriceValueHeld afterSource
Jun 16, 2026Grant or award from the company+26,455163,808 directFiling · EDGAR
Jun 16, 2026Grant or award from the company
Stock Option (Right to Buy)
+39,71539,715 directFiling · EDGAR
Jun 18, 2025Grant or award from the company+41,551137,353 directFiling · EDGAR
Jun 18, 2025Grant or award from the company
Stock Option (Right to Buy)
+54,05954,059 directFiling · EDGAR
Jun 14, 2024Grant or award from the company
Stock Option (Right to Buy)
+40,24340,243 directFiling · EDGAR
Jun 15, 2023Grant or award from the company
Stock Option (Right to Buy)
+49,23749,237 directFiling · EDGAR
Jun 15, 2022Grant or award from the company+95,80295,802 directFiling · EDGAR
Jun 15, 2022Grant or award from the company
Stock Option (Right to Buy)
+100,000100,000 directFiling · EDGAR
Mar 11, 2021Grant or award from the company
Stock Option (Right to Buy)
+63,68763,687 directFiling · EDGAR

Intellia Therapeutics NTLA Director · filings 2022 to 2026 · sold $96K · $85K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 9, 2026Grant or award from the company+9,20036,403 directFiling · EDGAR
Jun 9, 2026Grant or award from the company
Stock Option (right to buy)
+13,30013,300 directFiling · EDGAR
Jun 11, 2025Grant or award from the company+8,00027,203 directFiling · EDGAR
Jun 11, 2025Grant or award from the company
Stock Option (right to buy)
+11,45011,450 directFiling · EDGAR
Apr 29, 2025Sale under a 10b5-1 plan−265$8.50$2K19,203 directFiling · EDGAR
Jan 29, 2025Sale under a 10b5-1 plan−265$9.97$3K19,468 directFiling · EDGAR
Jun 12, 2024Grant or award from the company+7,73719,733 directFiling · EDGAR
Jun 12, 2024Grant or award from the company
Stock Option (right to buy)
+11,51511,515 directFiling · EDGAR
Oct 31, 2023Sale under a 10b5-1 plan−265$23.90$6K11,996 directFiling · EDGAR
Jul 31, 2023Sale under a 10b5-1 plan−265$42.33$11K12,261 directFiling · EDGAR
Jul 6, 2023Sale under a 10b5-1 plan−1,867$39.30$73K12,526 directFiling · EDGAR
Jun 14, 2023Grant or award from the company+4,42514,393 directFiling · EDGAR
Jun 14, 2023Grant or award from the company
Stock Option (right to buy)
+6,4736,473 directFiling · EDGAR
Jun 14, 2022Grant or award from the company+2,0149,968 directFiling · EDGAR
Jun 14, 2022Grant or award from the company
Stock Option (right to buy)
+2,9802,980 directFiling · EDGAR
Apr 28, 2022Grant or award from the company+7,9547,954 directFiling · EDGAR
Apr 28, 2022Grant or award from the company
Stock Option (Right to Buy)
+11,70011,700 directFiling · EDGAR

Cytokinetics CYTK Director · filings 2021 to 2026 · sold $216K · $216K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
May 27, 2026Grant or award from the company+2,85126,361 directFiling · EDGAR
May 27, 2026Grant or award from the company
Non-Qualified Stock Option (Right to Buy)
+4,3014,301 directFiling · EDGAR
May 15, 2025Sale under a 10b5-1 plan−1,454$29.73$43K23,510 directFiling · EDGAR
May 14, 2025Grant or award from the company+7,33324,964 directFiling · EDGAR
May 14, 2025Grant or award from the company
Non-Qualified Stock Option (Right to Buy)
+10,88010,880 directFiling · EDGAR
Jun 10, 2024Sale under a 10b5-1 plan−2,000$52.07$104K17,631 directFiling · EDGAR
May 15, 2024Grant or award from the company+5,60019,631 directFiling · EDGAR
May 15, 2024Grant or award from the company
Non-Qualified Stock Option (Right to Buy)
+3,6363,636 directFiling · EDGAR
Jul 7, 2023Sale under a 10b5-1 plan−2,000$34.12$68K14,031 directFiling · EDGAR
May 10, 2023Grant or award from the company+5,00016,031 directFiling · EDGAR
May 10, 2023Grant or award from the company
Non-Qualified Stock Option (Right to Buy)
+10,00010,000 directFiling · EDGAR
Oct 3, 2022Grant or award from the company+220$51.11$11K11,031 directFiling · EDGAR
Jul 1, 2022Grant or award from the company+274$41.00$11K10,811 directFiling · EDGAR
May 10, 2022Grant or award from the company+5,00010,537 directFiling · EDGAR
May 10, 2022Grant or award from the company
Non-Qualified Stock Option (right to buy)
+10,00010,000 directFiling · EDGAR
Apr 1, 2022Grant or award from the company+293$38.38$11K5,537 directFiling · EDGAR
Jan 3, 2022Grant or award from the company+244$46.00$11K5,244 directFiling · EDGAR
May 12, 2021Grant or award from the company+5,0005,000 directFiling · EDGAR
May 12, 2021Grant or award from the company
Non-Qualified Stock Option (right to buy)
+10,00010,000 directFiling · EDGAR
Feb 17, 2021Grant or award from the company
Non-Qualified Stock Option (right to buy)
+35,000$21.86$765K35,000 directFiling · EDGAR
All 57 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Oct 20, 2026Form 4Veracyte VCYTFiling · EDGAR
Sep 3, 2026Form 4Veracyte VCYTFiling · EDGAR
Sep 1, 2026Form 144Veracyte VCYTFiling · EDGAR
Jun 18, 2026Form 4Ardelyx ARDXFiling · EDGAR
Jun 15, 2026Form 4Veracyte VCYTFiling · EDGAR
Jun 10, 2026Form 4Intellia Therapeutics NTLAFiling · EDGAR
May 27, 2026Form 4Cytokinetics CYTKFiling · EDGAR
Jun 23, 2025Form 4Ardelyx ARDXFiling · EDGAR
Jun 23, 2025Form 4Veracyte VCYTFiling · EDGAR
Jun 17, 2025Form 4Veracyte VCYTFiling · EDGAR
Jun 13, 2025Form 144Veracyte VCYTFiling · EDGAR
Jun 13, 2025Form 4Intellia Therapeutics NTLAFiling · EDGAR
May 15, 2025Form 144Cytokinetics CYTKFiling · EDGAR
May 15, 2025Form 4Cytokinetics CYTKFiling · EDGAR
May 14, 2025Form 4Cytokinetics CYTKFiling · EDGAR
May 1, 2025Form 4Intellia Therapeutics NTLAFiling · EDGAR
Jan 31, 2025Form 4Intellia Therapeutics NTLAFiling · EDGAR
Jun 17, 2024Form 4Ardelyx ARDXFiling · EDGAR
Jun 17, 2024Form 4Veracyte VCYTFiling · EDGAR
Jun 14, 2024Form 4Intellia Therapeutics NTLAFiling · EDGAR
Jun 11, 2024Form 4Veracyte VCYTFiling · EDGAR
Jun 10, 2024Form 144Cytokinetics CYTKFiling · EDGAR
Jun 10, 2024Form 4Cytokinetics CYTKFiling · EDGAR
May 30, 2024Form 4Veracyte VCYTFiling · EDGAR
May 28, 2024Form 144Veracyte VCYTFiling · EDGAR
May 16, 2024Form 4Cytokinetics CYTKFiling · EDGAR
Nov 2, 2023Form 4Intellia Therapeutics NTLAFiling · EDGAR
Aug 2, 2023Form 4Intellia Therapeutics NTLAFiling · EDGAR
Jul 31, 2023Form 144Intellia Therapeutics NTLAFiling · EDGAR
Jul 10, 2023Form 4Intellia Therapeutics NTLAFiling · EDGAR
Jul 7, 2023Form 144Cytokinetics CYTKFiling · EDGAR
Jul 7, 2023Form 4Cytokinetics CYTKFiling · EDGAR
Jul 6, 2023Form 144Intellia Therapeutics NTLAFiling · EDGAR
Jun 21, 2023Form 4Veracyte VCYTFiling · EDGAR
Jun 16, 2023Form 4Ardelyx ARDXFiling · EDGAR
Jun 16, 2023Form 4Intellia Therapeutics NTLAFiling · EDGAR
Jun 13, 2023Form 4Veracyte VCYTFiling · EDGAR
Jun 1, 2023Form 4Veracyte VCYTFiling · EDGAR
May 30, 2023Form 144Veracyte VCYTFiling · EDGAR
May 18, 2023Form 4Cytokinetics CYTKFiling · EDGAR
Oct 5, 2022Form 4Cytokinetics CYTKFiling · EDGAR
Jul 12, 2022Form 4Cytokinetics CYTKFiling · EDGAR
Jun 17, 2022Form 4Ardelyx ARDXFiling · EDGAR
Jun 16, 2022Form 4Veracyte VCYTFiling · EDGAR
Jun 16, 2022Form 4Intellia Therapeutics NTLAFiling · EDGAR
May 11, 2022Form 4Cytokinetics CYTKFiling · EDGAR
May 2, 2022Form 4Intellia Therapeutics NTLAFiling · EDGAR
May 2, 2022Form 3Intellia Therapeutics NTLAFiling · EDGAR
Apr 1, 2022Form 4Cytokinetics CYTKFiling · EDGAR
Jan 4, 2022Form 4Cytokinetics CYTKFiling · EDGAR
May 13, 2021Form 4Cytokinetics CYTKFiling · EDGAR
Mar 23, 2021Form 4Veracyte VCYTFiling · EDGAR
Mar 23, 2021Form 3Veracyte VCYTFiling · EDGAR
Mar 15, 2021Form 4Ardelyx ARDXFiling · EDGAR
Mar 15, 2021Form 3Ardelyx ARDXFiling · EDGAR
Feb 18, 2021Form 3Cytokinetics CYTKFiling · EDGAR
Feb 18, 2021Form 4Cytokinetics CYTKFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.